Report Offers Hope, Outlines 537 New Drugs In Development For Neurological Disorders
A report released this week by some of the nation’s leading biopharmaceutical research companies says 537 medicines are currently being developed for the nearly 100 million Americans who are affected by neurological disorders. The list, compiled by the Pharmaceutical Research and Manufacturers of America (PhRMA), includes 95 medicines for brain tumors, 92 for Alzheimer’s disease, 46 for chronic pain and many more impacting conditions ranging from multiple sclerosis (MS) to amyotrophic lateral sclerosis (ALS) to Parkinson’s disease to migraine.
Emergency room physician and PhRMA vice president, Mike Ybarra, M.D., said the report, titled “Medicines in Development for Neurological Disorders 2018 Report,” shows a “relentless commitment” by scientists to treat and cure some of the most debilitating diseases that affect 1 in 3 Americans and cost some $800 billion in care annually.
Most importantly to realize, said Ybarra, is that the new report tells Americans and the world that there is research and development happening on diseases where no treatments exist as well as continuing study on therapeutics for diseases for which some treatments already exist and can be improved upon.
